Furthermore, Voso et al. observed that FA gene mutations, including FANCA, were prevalent in therapy-related myeloid neoplasms, highlighting their potential role in the pathogenesis of secondary AML [26]. This evidence concerns the gene FANCA and myeloid neoplasm.